Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Infiltration of COX-2–expressing macrophages is a prerequisite for IL-1β–induced neovascularization and tumor growth
Shintaro Nakao, … , Michihiko Kuwano, Mayumi Ono
Shintaro Nakao, … , Michihiko Kuwano, Mayumi Ono
Published November 1, 2005
Citation Information: J Clin Invest. 2005;115(11):2979-2991. https://doi.org/10.1172/JCI23298.
View: Text | PDF
Research Article Angiogenesis

Infiltration of COX-2–expressing macrophages is a prerequisite for IL-1β–induced neovascularization and tumor growth

  • Text
  • PDF
Abstract

Inflammatory angiogenesis is a critical process in tumor progression and other diseases. The inflammatory cytokine IL-1β promotes angiogenesis, tumor growth, and metastasis, but its mechanisms remain unclear. We examined the association between IL-1β–induced angiogenesis and cell inflammation. IL-1β induced neovascularization in the mouse cornea at rates comparable to those of VEGF. Neutrophil infiltration occurred on day 2. Macrophage infiltration occurred on days 4 and 6. The anti–Gr-1 Ab-induced depletion of infiltrating neutrophils did not affect IL-1β– or VEGF-induced angiogenesis. The former was reduced in monocyte chemoattractant protein-1–deficient (MCP-1–/–) mice compared with wild-type mice. After day 4, clodronate liposomes, which kill macrophages, reduced IL-1β–induced angiogenesis and partially inhibited VEGF-induced angiogenesis. Infiltrating macrophages near the IL-1β–induced neovasculature were COX-2 positive. Lewis lung carcinoma cells expressing IL-1β (LLC/IL-1β) developed neovasculature with macrophage infiltration and enhanced tumor growth in wild-type but not MCP-1–/– mice. A COX-2 inhibitor reduced tumor growth, angiogenesis, and macrophage infiltration in LLC/IL-1β. Thus, macrophage involvement might be a prerequisite for IL-1β–induced neovascularization and tumor progression.

Authors

Shintaro Nakao, Takashi Kuwano, Chikako Tsutsumi-Miyahara, Shu-ichi Ueda, Yusuke N. Kimura, Shinjiro Hamano, Koh-hei Sonoda, Yasuo Saijo, Toshihiro Nukiwa, Robert M. Strieter, Tatsuro Ishibashi, Michihiko Kuwano, Mayumi Ono

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
IL-1β– and VEGF-induced angiogenesis and inflammatory cell infiltration ...
IL-1β– and VEGF-induced angiogenesis and inflammatory cell infiltration in mouse corneas. (A) Neovascularization 6 days after implanting Hydron pellets containing human or mouse IL-1β or mouse VEGF at the doses shown into male BALB/c mouse corneas. hIL-1β, human IL-1β; mIL-1β, mouse IL-1β; mVEGF, mouse VEGF. (B) Corneal neovascularization induced by human IL-1β (30 ng) or mouse VEGF (200 ng) at the indicated time points. (C) Quantitative analysis of neovascularization on days 4 (white bars) and 6 (black bars). Areas are expressed in mm2. Bars show the mean ± SD of independent experiments (n = 6 or 7). (D) Corneas implanted with IL-1β or VEGF stained by H&E at the indicated time points. (E) Corneal sections on days 2 or 6 after IL-1β–pellet implantation, labeled immunohistochemically (brown) for Gr-1, which was detected in infiltrating cells on days 2 and 6, and F4/80, which was detected on day 6. (F) FACS analysis of infiltrating cells from IL-1β– or VEGF-implanted corneas (n = 5) at the indicated times. Cells were stained with PE-CD11b mAb and FITC–Gr-1 or FITC-F4/80 mAb. The percentages of infiltrating CD11b+Gr-1+ cells in IL-1β–implanted corneas were 53.5% ± 10.4% (day 2), 15.8% ± 4.9% (day 4), and 3.15% ± 0.27% (day 6). The percentages of infiltrating CD11b+Gr-1+ cells in VEGF-implanted corneas were 2.99% ± 1.37% (day 2), 1.95% ± 0.75% (day 4), and 1.08% ± 0.74% (day 6). The percentages of infiltrating CD11b+F4/80+ cells in IL-1β–implanted corneas were 1.85% ± 1.28% (day 2), 5.56% ± 1.61% (day 4), and 5.52% ± 1.14% (day 6). The percentages of infiltrating CD11b+F4/80+ cells in VEGF-implanted corneas were 0.81% ± 0.47% (day 2), 1.30% ± 1.03% (day 4), and 1.90% ± 0.98% (day 6).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts